videopokertrainingsoftware| Shengfang Pharmaceutical R & D and CMAC jointly established the Heart Safety Industry Alliance to jointly open a new chapter in heart safety!

On May 15, the high-profile CMAC Heart Safety Industry Alliance was solemnly held in Shanghai Shengfang Medical Research and Development headquarters. This event brought together many elites and experts in the field of heart safety to discuss the core role of heart safety in the whole life cycle of drugs, as well as the cutting-edge application of digital intelligence technology in new drug research and development.

Qi Xiaomei

The event was hosted by Ms. Qi Xiaomei, Vice President of Medical Research and Development, General Manager of Cardiac Safety Division and head of CMAC Cardiac Safety Industry Alliance.

Li Jingcheng

At the beginning of the meeting, Li Jingcheng, chairman of CMAC and head of CMAC Heart Safety Industry Alliance, delivered an ebullient welcome speech, saying that in 2024 CMAC was officially approved by NGO Organization (Beijing Cooperative Medical Innovation Promotion Center), with a new identity and new height, CMAC will unite all parties to build an innovation ecology with a more open and inclusive attitude. Teachers are welcome to participate in various activities of CMAC and put forward a lot of valuable suggestions. Finally, it also points out the direction for the follow-up activities of the Heart Safety Industry Alliance, which should be more practical and approachable.

01 keynote speech

Then, the experts and celebrities brought a series of wonderful topics to share. From the point of view of the overview of cardiac safety assessment, preclinical cardiovascular system safety assessment, in vitro arrhythmia assessment, and the application of AIGC in the field of medicine, the experts areVideopokertrainingsoftwareWe have revealed the deep secret of medical safety.

Qi Xiaomei

Ms. Qi Xiaomei shared the topic of "Overview of Cardiac Safety Assessment in the whole Life cycle of drugs". From the aspects of the impact of cardiovascular safety on all stages of the drug life cycle, the guiding principles of ICH, and the development of new technologies to break through the limitations of the existing evaluation system, we outlined the importance of cardiac safety assessment in the whole process of drug development and marketing. She pointed out that "safety" in new drug research and development is a complete system, and different participants have different dimensions of consideration. The safety of medication for patients is not only related to the physical and chemical properties of the drug itself, but also closely related to the scheme design and development process of clinical trials, which requires the joint efforts of all participants.

Xie Renzong

Dr. Xie Renzong, Vice President of Medici Toxicology Research, shared the theme of "preclinical cardiovascular system safety evaluation considerations". He analyzed how to fully consider cardiovascular system safety at the early stage of drug development from three aspects of cardiovascular system safety pharmacology research: in vitro trials, in vivo trials, and new methods / techniques.

Diao Lei

The theme shared by Dr. Diao Lei, head of Clinical Pharmacology of Fosun Global R & D Center is "CIPA"VideopokertrainingsoftwareComprehensive In Vitro Proarrhythmia Assay ", from the history and current situation of CIPA, the four components of CIPA, CIPA strategy and other directions, shows us advanced techniques and methods for the evaluation of in vitro arrhythmias, helping to make more informed decisions in the early stages of drug development.

Li Zhuo

The sharing of "Security considerations for the Application of AIGC in the Medical Field" brought by Mr. Li Zhuo, founder and CEO of HydroX AI, has pushed the combination of artificial intelligence and medical security to a new height. He stressed the important role of AIGC in the research and development of new drugs and pointed out the safety considerations that need to be paid attention to in the process of application.

Li Haiyan

Professor Li Haiyan, director of the Clinical Research Center of the third Hospital of Beijing Medical University, brought a sharing theme of "key points of attention in ICH E14 C-QTc research implementation". In the form of ten questions and ten answers, from hot topics such as QT research background and latest guidelines implementation concerns, in-depth analysis of the key elements in the implementation of C-QTc research.

Li Jizong

Professor Li Jizong, director of Shanghai Biopharmaceutical Science and Technology Development Center, brought a sharing entitled "developing Computational Biology to promote Biopharmaceutical Innovation". He demonstrated the importance of developing computational biology in promoting medical innovation from three aspects: the nature and requirements of biomedical innovation, the new driving force of scientific paradigm change (310328), and the empowering development of computational biology.

02 round table discussion

Round table discussion session, Diao Lei, Xie Renzong, Li